Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Cancer Discov. 2016 Sep 23;7(1):86–101. doi: 10.1158/2159-8290.CD-16-0127

Figure 7. KEAP1/NRF2 mutation status predicts local failure after radiotherapy in human NSCLC.

Figure 7

(A) Clinical characteristics of a cohort of stage I–III NSCLC patients treated with curative intent RT and analyzed for KEAP1/NRF2 mutation status using targeted next generation sequencing.

(B–C) Association of KEAP1/NRF2 mutations with local failure in NSCLC patients treated with radiotherapy. (B) Entire cohort. (C) Stages II–III patients treated with conventionally fractionated radiotherapy or chemoradiotherapy.

(D) Non-invasive identification of KEAP1 mutation status in circulating tumor DNA (ctDNA) isolated from pre-treatment plasma samples of 7 patients from the cohort in (A) using CAPP-Seq.

(E) Monitoring of ctDNA in a KEAP1 mutant patient from (D) treated with chemoradiation. CR, complete response; LF, local failure; carbo, carboplatin.

(F) Clinical characteristics of a validation cohort of stage I–III NSCLC patients treated with curative intent RT and analyzed for KEAP1/NRF2 mutation status using targeted next generation sequencing.